Loading...
Loading...
Bristol-Myers
Squibb Company
BMY and Pfizer
Inc.
PFE today announced the results of the Phase 3
AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS®
(apixaban) over a one-year period compared to placebo for the prevention
of recurrent venous thromboembolism (VTE) in 2,486 patients who had
already completed 6 to 12 months of anticoagulation treatment for VTE,
including deep vein thrombosis (DVT) or pulmonary embolism (PE). In the
trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily,
demonstrated superiority versus placebo in the reduction of the
composite endpoint of symptomatic, recurrent VTE and death from any
cause (11.6% in the placebo group, compared with 3.8% and 4.2% in the
ELIQUIS
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in